Announced
Completed
Financials
Tags
United States
biotechnology
Biotechnology
biopharma
therapeutics
Public
Friendly
Acquisition
Domestic
Majority
Single Bidder
Completed
Synopsis
XOMA, a biotechnology royalty aggregator, completed the acquisition of Kinnate Biopharma, a clinical-stage precision oncology company, for $122m. Kinnate Biopharma is a clinical-stage precision oncology company founded with a mission to inspire hope in those battling cancer by expanding on the promise of targeted therapies.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.